Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

On the Importance of Extracting the Needle from the Haystack.

Cancer biotherapy & radiopharmaceuticals·2026

Same author

A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same author

Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025

Same author

Investigation and preparation of a TREN-based bifunctional chelator for <sup>89</sup>Zr.

Dalton transactions (Cambridge, England : 2003)·2025

Same author

Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: May 16, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Molecular pathways: targeted α-particle radiation therapy.

Kwamena E Baidoo¹, Kwon Yong, Martin W Brechbiel

¹Radioimmune & Inorganic Chemistry Section, ROB, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|December 12, 2012

Summary

Targeted alpha-therapy (TAT) uses alpha particles for precise cancer treatment, minimizing damage to healthy tissues. Further research is needed to fully understand the molecular pathways involved in DNA repair and cell death following TAT.

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Related Experiment Videos

Last Updated: May 16, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Area of Science:

Oncology
Radiation Oncology
Molecular Biology

Background:

Alpha-particle radiation, a Helium-4 nucleus, offers high cytotoxicity with limited tissue penetration.
Targeted alpha-therapy (TAT) leverages this property for precise cancer cell targeting, minimizing normal tissue effects.
Despite clinical interest and trials, the precise molecular mechanisms of TAT-induced DNA damage and cellular response remain incompletely understood.

Purpose of the Study:

To provide an overview of the current understanding of molecular pathways involved in DNA damage response and repair following targeted alpha-therapy.
To highlight the clinical translation status of TAT and other alpha-emitter radionuclide therapies.

Main Methods:

Review of existing literature on high linear energy transfer (LET) radiation effects.
Analysis of molecular pathways implicated in DNA damage and repair.
Summary of clinical trial data and translation of alpha-emitter therapies.

Main Results:

High LET alpha-radiation causes significant DNA damage, primarily double-strand breaks.
Cellular responses involve complex pathways for DNA repair and cell fate determination.
Several alpha-emitters, including (225)Ac, (211)At, (213)Bi, (212)Pb, and (223)Ra, are in clinical development or use.

Conclusions:

TAT presents a promising therapeutic strategy for various cancers, especially minimal or compartmentalized disease.
Further elucidation of molecular mechanisms is crucial for optimizing TAT efficacy and safety.
Clinical translation of TAT and related alpha-emitter therapies is advancing globally.